ScholarSphere

The Potential of Cannabichromene (CBC) as a Therapeutic Agent

There is a growing interest in the use of medicinal plants to treat a variety of diseases, and one of the most commonly used medicinal plants globally is Cannabis sativa. The two most abundant cannabinoids (Δ9-tetrahydrocannabinol and cannabidiol) have been governmentally approved to treat selected medical conditions; however, the plant produces over 100 cannabinoids, including cannabichromene (CBC). While the cannabinoids share a common precursor molecule, cannabigerol, they are structurally and pharmacologically unique. These differences may engender differing therapeutic potentials. In this review, we will examine what is currently known about CBC with regards to pharmacodynamics, pharmacokinetics, and receptor profile. We will also discuss the therapeutic areas that have been examined for this cannabinoid, notably antinociceptive, antibacterial, and anti-seizure activities. Finally, we will discuss areas where new research is needed and potential novel medicinal applications for CBC.

Significance Statement: Cannabichromene (CBC) has been suggested to have disparate therapeutic benefits such as anti-inflammatory, anticonvulsant, antibacterial, and antinociceptive effects. Most of the focus on the medical benefits of cannabinoids has been focused on THC and CBD. The preliminary studies on CBC indicate that this phytocannabinoid may have unique therapeutic potential that warrants further investigation. Following easier access to hemp, CBC products are commercially available over-the-counter and are being widely utilized with little or no evidence of their safety or efficacy.

Files

Metadata

Work Title The Potential of Cannabichromene (CBC) as a Therapeutic Agent
Access
Open Access
Creators
  1. Diana E. Sepulveda
  2. Kent E. Vrana
  3. Joshua J. Kellogg
  4. Jordan E. Bisanz
  5. Dhimant Desai
  6. Nicholas M. Graziane
  7. Wesley M. Raup-Konsavage
Keyword
  1. Cannabichromene
  2. Cannabinoids
  3. Therapeutic Agents
  4. Cannabinoid
  5. Cannabis Sativa
  6. Medicinal Plants
  7. Pharmacodynamics
  8. Cannabidiol
  9. Cannabigerol
  10. Therapeutic Potential
  11. Pharmacokinetics
  12. Pharmacokinetic Profile
  13. Pharmacokinetics Pharmacodynamics (Pk Pd)
  14. δ9 Tetrahydrocannabinol (δ9 Thc)
  15. Antiseizure Activity
  16. Receptor Profile
  17. Therapeutic Area
  18. Medicinal Plant
  19. Medicinal Uses
  20. Diseases
  21. Receptor
  22. Tetrahydrocannabinol
  23. Antiinfective Agent
  24. Antinociceptive
  25. Medical Conditions
  26. Precursor Molecules
License CC BY-NC 4.0 (Attribution-NonCommercial)
Work Type Article
Publisher
  1. Journal of Pharmacology and Experimental Therapeutics
Publication Date May 1, 2024
Publisher Identifier (DOI)
  1. 10.1124/jpet.124.002166
Related URLs
  1. https://doi.org/10.1124/jpet.124.002166
Deposited February 10, 2025

Versions

Analytics

Collections

This resource is currently not in any collection.

Work History

Version 1
published

  • Created

    February 10, 2025 10:29 by jjk6146

  • Updated

    February 10, 2025 10:29 by [unknown user]

  • Added Creator Diana E Sepulveda

    February 10, 2025 10:29 by jjk6146

  • Added Creator Kent Vrana

    February 10, 2025 10:29 by jjk6146

  • Added Creator Joshua Kellogg

    February 10, 2025 10:29 by jjk6146

  • Added Creator Jordan Bisanz

    February 10, 2025 10:29 by jjk6146

  • Added Creator Dhimant Desai

    February 10, 2025 10:29 by jjk6146

  • Added Creator Nicholas M. Graziane

    February 10, 2025 10:29 by jjk6146

  • Added Creator Wesley Raup-Konsavage

    February 10, 2025 10:29 by jjk6146

  • Updated Keyword, Publisher, Publisher Identifier (DOI), and 3 more Show Changes

    February 10, 2025 10:29 by jjk6146

    Keyword
    • Cannabichromene, Cannabinoids, Therapeutic Agents, Cannabinoid, Cannabis Sativa, Medicinal Plants, Pharmacodynamics, Cannabidiol, Cannabigerol, Therapeutic Potential, Pharmacokinetics, Pharmacokinetic Profile, Pharmacokinetics Pharmacodynamics (Pk Pd), δ9 Tetrahydrocannabinol (δ9 Thc), Antiseizure Activity, Receptor Profile, Therapeutic Area, Medicinal Plant, Medicinal Uses, Diseases, Receptor, Tetrahydrocannabinol, Antiinfective Agent, Antinociceptive, Medical Conditions, Precursor Molecules
    Publisher
    • Journal of Pharmacology and Experimental Therapeutics
    Publisher Identifier (DOI)
    • 10.1124/jpet.124.002166
    Related URLs
    • https://jpet.aspetjournals.org/content/jpet/early/2024/05/22/jpet.124.002166.full.pdf
    Description
    • There is a growing interest in the use of medicinal plants to treat a variety of diseases, and one of the most commonly used medicinal plants globally is <i>Cannabis sativa</i>. The two most abundant cannabinoids (Δ<sup>9</sup>-tetrahydrocannabinol and cannabidiol) have been governmentally approved to treat selected medical conditions; however, the plant produces over 100 cannabinoids, including cannabichromene (CBC). While the cannabinoids share a common precursor molecule, cannabigerol, they are structurally and pharmacologically unique. These differences may engender differing therapeutic potentials. In this review, we will examine what is currently known about CBC with regards to pharmacodynamics, pharmacokinetics, and receptor profile. We will also discuss the therapeutic areas that have been examined for this cannabinoid, notably antinociceptive, antibacterial, and anti-seizure activities. Finally, we will discuss areas where new research is needed and potential novel medicinal applications for CBC.<br><b>Significance Statement</b> Cannabichromene (CBC) has been suggested to have disparate therapeutic benefits such as anti-inflammatory, anticonvulsant, antibacterial, and antinociceptive effects. Most of the focus on the medical benefits of cannabinoids has been focused on THC and CBD. The preliminary studies on CBC indicate that this phytocannabinoid may have unique therapeutic potential that warrants further investigation. Following easier access to hemp, CBC products are commercially available over-the-counter and are being widely utilized with little or no evidence of their safety or efficacy.
    Publication Date
    • 2024-05-01
  • Updated

    February 10, 2025 10:29 by jjk6146

  • Updated

    February 10, 2025 10:29 by jjk6146

  • Updated Creator Diana E Sepulveda

    February 10, 2025 10:30 by jjk6146

  • Updated Creator Kent Vrana

    February 10, 2025 10:30 by jjk6146

  • Updated Creator Joshua Kellogg

    February 10, 2025 10:30 by jjk6146

  • Updated Creator Jordan Bisanz

    February 10, 2025 10:30 by jjk6146

  • Updated Creator Dhimant Desai

    February 10, 2025 10:30 by jjk6146

  • Updated Creator Nicholas M. Graziane

    February 10, 2025 10:30 by jjk6146

  • Updated Creator Wesley Raup-Konsavage

    February 10, 2025 10:30 by jjk6146

  • Added Sepulveda et al. - 2024 - The Potential of Cannabichromene (CBC) as a Therap.pdf

    February 10, 2025 10:30 by jjk6146

  • Updated License Show Changes

    February 10, 2025 10:30 by jjk6146

    License
    • https://creativecommons.org/licenses/by-nc/4.0/
  • Published

    February 10, 2025 10:30 by jjk6146

  • Updated

    February 10, 2025 21:04 by [unknown user]

  • Updated Description, Related URLs Show Changes

    April 03, 2025 11:48 by avs5190

    Description
    • There is a growing interest in the use of medicinal plants to treat a variety of diseases, and one of the most commonly used medicinal plants globally is <i>Cannabis sativa</i>. The two most abundant cannabinoids (Δ<sup>9</sup>-tetrahydrocannabinol and cannabidiol) have been governmentally approved to treat selected medical conditions; however, the plant produces over 100 cannabinoids, including cannabichromene (CBC). While the cannabinoids share a common precursor molecule, cannabigerol, they are structurally and pharmacologically unique. These differences may engender differing therapeutic potentials. In this review, we will examine what is currently known about CBC with regards to pharmacodynamics, pharmacokinetics, and receptor profile. We will also discuss the therapeutic areas that have been examined for this cannabinoid, notably antinociceptive, antibacterial, and anti-seizure activities. Finally, we will discuss areas where new research is needed and potential novel medicinal applications for CBC.<br><b>Significance Statement</b> Cannabichromene (CBC) has been suggested to have disparate therapeutic benefits such as anti-inflammatory, anticonvulsant, antibacterial, and antinociceptive effects. Most of the focus on the medical benefits of cannabinoids has been focused on THC and CBD. The preliminary studies on CBC indicate that this phytocannabinoid may have unique therapeutic potential that warrants further investigation. Following easier access to hemp, CBC products are commercially available over-the-counter and are being widely utilized with little or no evidence of their safety or efficacy.
    • There is a growing interest in the use of medicinal plants to treat a variety of diseases, and one of the most commonly used medicinal plants globally is _Cannabis sativa_. The two most abundant cannabinoids (Δ<sup>9</sup>-tetrahydrocannabinol and cannabidiol) have been governmentally approved to treat selected medical conditions; however, the plant produces over 100 cannabinoids, including cannabichromene (CBC). While the cannabinoids share a common precursor molecule, cannabigerol, they are structurally and pharmacologically unique. These differences may engender differing therapeutic potentials. In this review, we will examine what is currently known about CBC with regards to pharmacodynamics, pharmacokinetics, and receptor profile. We will also discuss the therapeutic areas that have been examined for this cannabinoid, notably antinociceptive, antibacterial, and anti-seizure activities. Finally, we will discuss areas where new research is needed and potential novel medicinal applications for CBC.<br>
    • Significance Statement: Cannabichromene (CBC) has been suggested to have disparate therapeutic benefits such as anti-inflammatory, anticonvulsant, antibacterial, and antinociceptive effects. Most of the focus on the medical benefits of cannabinoids has been focused on THC and CBD. The preliminary studies on CBC indicate that this phytocannabinoid may have unique therapeutic potential that warrants further investigation. Following easier access to hemp, CBC products are commercially available over-the-counter and are being widely utilized with little or no evidence of their safety or efficacy.
    Related URLs
    • https://jpet.aspetjournals.org/content/jpet/early/2024/05/22/jpet.124.002166.full.pdf
    • https://doi.org/10.1124/jpet.124.002166
  • Renamed Creator Diana E. Sepulveda Show Changes

    April 03, 2025 11:49 by avs5190

    • Diana E Sepulveda
    • Diana E. Sepulveda
  • Renamed Creator Kent E. Vrana Show Changes

    April 03, 2025 11:49 by avs5190

    • Kent Vrana
    • Kent E. Vrana
  • Renamed Creator Joshua J. Kellogg Show Changes

    April 03, 2025 11:49 by avs5190

    • Joshua Kellogg
    • Joshua J. Kellogg
  • Renamed Creator Jordan E. Bisanz Show Changes

    April 03, 2025 11:49 by avs5190

    • Jordan Bisanz
    • Jordan E. Bisanz
  • Renamed Creator Wesley M. Raup-Konsavage Show Changes

    April 03, 2025 11:49 by avs5190

    • Wesley Raup-Konsavage
    • Wesley M. Raup-Konsavage